# An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

> **NCT05356351** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance

## Interventions

- **DRUG:** RC48- ADC

## Key facts

- **NCT ID:** NCT05356351
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-05-01
- **Primary completion:** 2023-07-01
- **Final completion:** 2027-07-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-05-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05356351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05356351, "An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05356351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*